The adaptive stroma joining the antiangiogenic resistance front.
Level V
Where this comes from
- Record sourced from PubMed, PMID 21436579.
- Also identified by DOI 10.1172/JCI46430 and PMC identifier 3069791.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Resistance to antiangiogenic therapies in cancer involves both tumor cells and stromal components, but their relative contributions differ in each cancer subtype. In this issue of the JCI, Cascone et al. describe a stromal adaptation to antiangiogenic therapy in non-small cell lung carcinoma (NSCLC) models that include EGFR-driven vascular remodeling promoting resistance to VEGF inhibition. Their results suggest that the added benefit of dual VEGF/R and EGFR targeting in these models could be clinically relevant to fight resistance in NSCLC patients.
Medical subject headings
- Angiogenesis Inhibitors
- Drug Resistance, Neoplasm